Skip to content

The Impact of Dementia and Neurocognitive Disorders on Hypertension Treatment in the Elderly

The Impact of Dementia and Neurocognitive Disorders on Hypertension Treatment in the Very Elderly: the TAHOC Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05845736
Acronym
TAHOC
Enrollment
353
Registered
2023-05-06
Start date
2022-01-01
Completion date
2022-12-12
Last updated
2023-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurocognitive Disorders, Dementia, Hypertension, Aged, 80 and Over

Keywords

Neurocognitive Disorders, Dementia, Hypertension, Aged, 80 and over

Brief summary

Neurocognitive disorders and hypertension occur commonly with aging. While, by definition, older adults are at high cardiovascular risk, there is no guideline exist currently on blood pressure management of elderly hypertension. However, studies have shown that in aging adults, high blood pressure helps prevent against cognitive decline, and low blood pressure on antihypertensive drugs could accelerate it. This study aims at investigating if pharmacological treatment of hypertension in the very elderly is influenced by presence and severity of neurocognitive disorders. Our research hypothesis is that the drug management of hypertension in patients 80 years of age or older more is all the less aggressive as the neurocognitive disorders are advanced.

Interventions

number of hypertensive drugs

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
80 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* to be 80 years of age * with history of hypertension and/or on hypertensive drug(s)

Exclusion criteria

* legal protection measure.

Design outcomes

Primary

MeasureTime frameDescription
number of antihypertensive agentsduring inclusionamong ACEI/ARB2, calcium channel blocker, thiazides and related, central antihypertensive beta blocker

Secondary

MeasureTime frameDescription
class of antihypertensive medicationsduring inclusionamong ACEI/ARB2, calcium channel blocker, thiazides and related, central antihypertensive beta blocker
systolic and diastolic blood pressureduring inclusionblood pressure measured with upper arm cuffs
orthostatic hypotensionduring inclusiona systolic blood pressure decrease of at least 20 mm Hg or a diastolic blood pressure decrease of at least 10 mm Hg within three minutes of standing

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026